AVANIR Pharmaceuticals to Present at UBS Warburg Global Life Sciences Conference

SAN DIEGO, Oct 7, 2002 /PRNewswire-FirstCall via COMTEX/ -- AVANIR Pharmaceuticals (Amex: AVN) announced today that it will present at the UBS Warburg Global Life Sciences Conference at 9:00 AM Eastern Time on Thursday, October 10, 2002. The conference is being held at The Plaza in New York. AVANIR's presentation will be webcast live for investors and available for replay for a period of 30 days following the conference. The presentation can be viewed at www.ubswarburg.com by following the link for Live Audio under the Global Life Sciences Conference heading.

President and Chief Executive Officer Gerald J. Yakatan, Ph.D. will provide an overview of the Company, focusing on AVANIR's current lead product, Neurodex, a late stage drug candidate to treat central nervous system disorders including pseudobulbar affect and neuropathic pain.

AVANIR Pharmaceuticals, based in San Diego, is a biopharmaceutical drug discovery and development company with a commercialized, FDA-approved product on the market. AVANIR is engaged in research, discovery and development of innovative drug products for chronic diseases and, through its subsidiary Xenerex Biosciences, antibody generation services. Further information about AVANIR and Xenerex can be found at www.avanir.com and www.xenerex.com .

The information contained in this press release, including any forward- looking statements contained herein, should be reviewed in conjunction with the company's Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect." Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

For further information, please contact: General Information, Kristen McNally, +1-310-407-6548, kmcnally@webershandwick.com, or Analysts/Investors, Tricia Ross, +1-310-407-6540, tross@webershandwick.com, or Media, Tim Grace, +1-312-640-6667, tgrace@webershandwick.com, all of FRB|Weber Shandwick, for AVANIR Pharmaceuticals; or investors, Patrice Saxon of AVANIR Pharmaceuticals, +1-858-622-5202, psaxon@avanir.com.

SOURCE AVANIR Pharmaceuticals

CONTACT:
General Information, Kristen McNally, +1-310-407-6548,
kmcnally@webershandwick.com, or Analysts/Investors, Tricia Ross,
+1-310-407-6540, tross@webershandwick.com, or Media, Tim Grace,
+1-312-640-6667, tgrace@webershandwick.com, all of FRB|Weber Shandwick, for
AVANIR Pharmaceuticals; or investors, Patrice Saxon of AVANIR Pharmaceuticals,
+1-858-622-5202, psaxon@avanir.com

URL:
http://www.ubswarburg.com
http://www.xenerex.com
http://www.avanir.com

Copyright (C) 2002 PR Newswire. All rights reserved.